𝔖 Bobbio Scriptorium
✦   LIBER   ✦

AKT/NF-κB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies

✍ Scribed by Raffaella Dell'Eva; Claudia Ambrosini; Nicola Vannini; Giovanna Piaggio; Adriana Albini; Nicoletta Ferrari

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
198 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND.

Leukemias are dependent on Akt/NF‐κB activation and angiogenesis.

METHODS.

The antiangiogenic Akt/NF‐κB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.

RESULTS.

Inhibition of cell proliferation is associated with induction of apoptosis and reduced VEGF secretion. Decreased cell invasion, metalloprotease production, and adhesion to endothelial cells observed in the presence of XN could prevent in vivo life‐threatening complications of leukostasis and tissue infiltration.

CONCLUSIONS.

As endothelial cells and hematopoietic cells are mutually correlated in their development and growth, targeting both tumor cells and endothelial cells with agents possessing cytotoxic and antiangiogenic activities may lead to synergistic antitumor effects interrupting a reciprocal stimulatory loop between leukemia and endothelial cells. Cancer 2007. © 2007 American Cancer Society.

📜 SIMILAR VOLUMES

Targeting NF-κB and induction of apoptos
Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells
✍ Noriko Kimura; Yoshitaka Miyakawa; Kanoko Kohmura; Kazuo Umezawa; Yasuo Ikeda; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 401 KB

A new NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction o

A novel NF-κB inhibitor DHMEQ selectivel
A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo
✍ Mariko Watanabe; Md. Zahidunnabi Dewan; Takamitu Okamura; Masataka Sasaki; Kinji 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 453 KB

Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i

Isosilybin A induces apoptosis in human
Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling
✍ Gagan Deep; Subhash C. Gangar; Nicholas H. Oberlies; David J. Kroll; Rajesh Agar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

## Abstract Prostate cancer (PCA) is the second most malignancy in American men. Advanced stage PCA cells possess unlimited replication potential as well as resistance to apoptosis. Therefore, targeting survival mechanisms and activating apoptotic machinery in PCA cells using nontoxic phytochemical

Effects of a novel NF-κB inhibitor, dehy
Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines
✍ Hong-ying Ruan; Muneyuki Masuda; Aya Ito; Kazuo Umezawa; Torahiko Nakashima; Ryu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Background: Recent studies provide evidence that the constitutive activation of nuclear factor-kappa b, nf-kappab plays a critical role in enhancing the growth of several types of malignancies, including head and neck squamous cell carcinoma (hnscc). ## Methods: In this study, we examined the